Skip to main content
Top

17-04-2024 | Respiratory Syncytial Virus Infection | RESEARCH

TRIM38 Induced in Respiratory Syncytial Virus-infected Cells Downregulates Type I Interferon Expression by Competing with TRIM25 to Bind RIG-I

Authors: Qingqing Sun, Xiao Han, Lingtong Meng, Hongru Li, Yijia Chen, Lizheng Yin, Chang Wang, Jiachao Wang, Miao Li, Xue Gao, Wenjian Li, Lin Wei, Cuiqing Ma

Published in: Inflammation

Login to get access

Abstract

Innate immune response is the first line of defense for the host against virus invasion. One important response is the synthesis and secretion of type I interferon (IFN-I) in the virus-infected host cells. Here, we found that respiratory syncytial virus (RSV) infection induced high expression of TRIM25, which belongs to the tripartite motif-containing (TRIM) family of proteins. TRIM25 bound and activated retinoic acid-inducible gene I (RIG-I) by K63-linked ubiquitination. Accordingly, RIG-I mediated the production of IFN-I mainly through the nuclear factor kappa-B (NF-κB) pathway in respiratory epithelial cells. Interestingly, IFN-I, in turn, promoted a high expression of TRIM38 which downregulated the expression of IFN-I by reducing the protein level of RIG-I by K48-linked ubiquitination. More importantly, the binding site of TRIM25 to RIG-I was found in the narrow 25th-43rd amino acid (aa) region of RIG-I N-terminus. In contrast, the binding sites of TRIM38 to RIG-I were found in a much wider amino acid region, which included the binding site of TRIM25 on RIG-I. As a result, TRIM38 inhibits the production of IFN-I by competing with TRIM25 for RIG-I binding. Thus, TRIM38 negatively regulates RIG-I activation to, in turn, downregulate IFN-I expression, thus interfering with host immune response. A negative feedback loop effectively "puts the brakes" on the reaction once host immune response is overactivated and homeostasis is unbalanced. We also discovered that TRIM25 bound RIG-I by a new K63-linked ubiquitination located at K-45 of the first caspase recruitment domain (CARD). Collectively, these results confirm an antagonism between TRIM38 and TRIM25 in regulating IFN-I production by affecting RIG-I activity following RNA virus infection.
Appendix
Available only for authorised users
Literature
13.
go back to reference Li, Jiao, Ling Xue, Jiachao Wang, Aihong Meng, Jiajun Qiao, Miao Li, Xiuli Wang, et al. 2022. Activation of the chemokine receptor CCR1 and preferential recruitment of Gαi suppress RSV replication: Implications for developing novel respiratory syncytial virus treatment strategies. Edited by Bryan R. G. Williams. Journal of Virology 96: e01309–e1322. https://doi.org/10.1128/jvi.01309-22.CrossRefPubMedPubMedCentral Li, Jiao, Ling Xue, Jiachao Wang, Aihong Meng, Jiajun Qiao, Miao Li, Xiuli Wang, et al. 2022. Activation of the chemokine receptor CCR1 and preferential recruitment of Gαi suppress RSV replication: Implications for developing novel respiratory syncytial virus treatment strategies. Edited by Bryan R. G. Williams. Journal of Virology 96: e01309–e1322. https://​doi.​org/​10.​1128/​jvi.​01309-22.CrossRefPubMedPubMedCentral
Metadata
Title
TRIM38 Induced in Respiratory Syncytial Virus-infected Cells Downregulates Type I Interferon Expression by Competing with TRIM25 to Bind RIG-I
Authors
Qingqing Sun
Xiao Han
Lingtong Meng
Hongru Li
Yijia Chen
Lizheng Yin
Chang Wang
Jiachao Wang
Miao Li
Xue Gao
Wenjian Li
Lin Wei
Cuiqing Ma
Publication date
17-04-2024
Publisher
Springer US
Published in
Inflammation
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-024-01979-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.